A randomized, double-blind, placebo-controlled, proof-of-concept trial of creatine monohydrate as adjunctive treatment for bipolar depression
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Depressive episodes are a major cause of morbidity and dysfunction in individuals suffering from bipolar disorder. Currently available treatments for this condition have limited efficacy and new therapeutic options are needed. Extensive research in the pathophysiology of bipolar disorder points to the existence of mitochondrial and bioenergetic dysfunction. We hypothesized that creatine monohydrate, a nutraceutical that works as a mitochondrial modulator, would be effective as an adjunctive therapy for bipolar depression. We conducted a double-blind trial in which 35 patients with bipolar disorder type I or II in a depressive episode by DSM-IV criteria and in use of regular medication for the treatment of this phase of the disease were randomly allocated into two adjunctive treatment groups for 6 weeks: creatine monohydrate 6 g daily (N = 17) or placebo (N = 18). Primary efficacy was assessed by the change in the Montgomery-Åsberg Depression Rating Scale (MADRS). We did not find a statistically significant difference in the comparison between groups for the change in score on the MADRS after 6 weeks in an intention-to-treat (ITT) analysis (p = 0.560; Cohen's d = 0.231). However, we found significant superiority of creatine add-on vs. placebo when we considered the remission criterion of a MADRS score ≤ 12 at week 6 analyzing the outcome of the 35 randomized patients on ITT (52.9% remission in the creatine group vs. 11.1% remission in the placebo group) and of the 23 completers (66.7% remission in the creatine group vs. 18.2% remission in the placebo group) (p = 0.012; OR = 9.0 and p = 0.036; OR = 9.0, respectively). Two patients who received creatine switched to hypomania/mania early in the trial. No clinically relevant physical side-effects were reported or observed. This proof-of-concept study, aiming to restore brain bioenergetics using an adjunctive mitochondrial modulator, is not conclusive on the efficacy of creatine add-on for bipolar depression, but suggests that this compound may have a role in the adjunctive treatment of this phase of the illness. Further investigation through randomized controlled trials with larger samples should be conducted to verify the efficacy of creatine supplementation for bipolar depression and also for subsyndromal depressive symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“and, in some instances, improve the efficacy of some anti-depressant medications [5,29,169,170,171,172].”
From Creatine in health and disease (2021) · cites this paper as [172]
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, early evidence indicates that creatine may be used as an adjunctive therapy in the actual management of clinical depression [71,72,73].”
From Creatine Supplementation in Children and Adolescents (2021) · cites this paper as [73]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · cited 6×
“Regarding the two patients who received creatine that were discontinued from the study due to worsening of depression, it is important to note that they did not present significant mixed features at baseline (total scores on YMRS = 0 and 2).”
MethodInfluentialMolecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Creatine and Creatinine Metabolism
Wyss, M., & Kaddurah-Daouk, R. (2000) · Physiological Reviews · doi:10.1152/physrev.2000.80.3.1107 · Cited by 2,950 · cited 1×
“Creatine is a non-essential dietary component found primarily in meat and fish and endogenously produced by the liver, kidneys and pancreas (Wyss and Kaddurah-Daouk 2000).”
BackgroundThe Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder
Rosa, A. R., Sánchez-Moreno, J., Martínez-Aran, A., Salamero, M., Torrent, C., Reinares, M., Comes, M., Colom, F., Van Riel, W., Ayuso-Mateos, J., et al. (2007) · Clinical Practice and Epidemiology in Mental Health · doi:10.1186/1745-0179-3-5 · Cited by 905
Calabrese, J. R., Keck, P. E., Macfadden, W., Minkwitz, M., Ketter, T. A., Weisler, R. H., Cutler, A. J., McCoy, R., Wilson, E., Mullen, J., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1351 · Cited by 883 · cited 1×
“Remission was defined as a MADRS score of 12 or less, as it has been defined in important published trials in the field (Calabrese et al. 2005; Loebel et al. 2014; McElroy et al. 2010; Young et al. 2010).”
MethodTohen, M., Frank, E., Bowden, C. L., Colom, F., Ghaemi, S. N., Yatham, L. N., Malhi, G. S., Calabrese, J. R., Nolen, W. A., Vieta, E., et al. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00726.x · Cited by 513
Berk, M., Copolov, D. L., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., & Bush, A. I. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.022 · Cited by 500
Direct antioxidant properties of creatine
Lawler, J. M., Barnes, W. S., Wu, G., Song, W., & Demaree, S. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.6164 · Cited by 448 · cited 1×
“Creatine has shown itself capable of removing superoxide and peroxynitrite with a direct antioxidant power even greater than that of glutathione (Lawler et al. 2002; Sestili et al. 2006).”
BackgroundAdjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses
Sarris, J., Murphy, J., Mischoulon, D., Papakostas, G. I., Fava, M., Berk, M., & Ng, C. H. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.15091228 · Cited by 436
Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia
Clay, H. B., Daws, S., & Konradi, C. (2011) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2010.08.007 · Cited by 399
Young, A. H., McElroy, S. L., Bauer, M., Philips, N., Chang, W., Olausson, B., Paulsson, B., Brecher, M., & EMBOLDEN I (Trial 001) Investigators (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04995gre · Cited by 390
Loebel, A., Cucchiaro, J., Silva, R., Kroger, H., Hsu, J., Sarma, K., & Sachs, G. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13070984 · Cited by 341
An updated meta-analysis of oxidative stress markers in bipolar disorder
Brown, N. C., Andreazza, A. C., & Young, L. T. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.04.005 · Cited by 335
Gardner, A., & Boles, R. G. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.030 · Cited by 333 · cited 2×
“…there is considerable evidence that mitochondrial and bioenergetic dysfunctions play a key role in the pathophysiology of unipolar 1 3 depression (Gardner and Boles 2011), these mechanisms may not exactly coincide with the ones implicated in bipolar disorder, so that we cannot simply extrapolate…”
BackgroundMcElroy, S. L., Weisler, R. H., Chang, W., Olausson, B., Paulsson, B., Brecher, M., Agambaram, V., Merideth, C., Nordenhem, A., Young, A. H., et al. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04942gre · Cited by 328
Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders
Rodriguez, M. C., MacDonald, J. R., Mahoney, D. J., Parise, G., Beal, M. F., & Tarnopolsky, M. A. (2007) · Muscle & Nerve · doi:10.1002/mus.20688 · Cited by 255
Kato, T., Takahashi, S., Shioiri, T., Murashita, J., Hamakawa, H., & Inubushi, T. (1994) · Journal of Affective Disorders · doi:10.1016/0165-0327(94)90116-3 · Cited by 223
Increase of total creatine in human brain after oral supplementation of creatine-monohydrate
Dechent, P., Pouwels, P. J. W., Wilken, B., Hanefeld, F., & Frahm, J. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.277.3.r698 · Cited by 221
Sestili, P., Martinelli, C., Bravi, G., Piccoli, G., Curci, R., Battistelli, M., Falcieri, E., Agostini, D., Gioacchini, A. M., & Stocchi, V. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.10.035 · Cited by 220
Scaini, G., Rezin, G. T., Carvalho, A. F., Streck, E. L., Berk, M., & Quevedo, J. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.06.040 · Cited by 179
Tarnopolsky, M. A. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.05.001 · Cited by 174
A model of the mitochondrial basis of bipolar disorder
Morris, G., Walder, K., McGee, S. L., Dean, O. M., Tye, S. J., Maes, M., & Berk, M. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.01.014 · Cited by 162
Lyoo, I. K., Kong, S. W., Sung, S. M., Hirashima, F., Parow, A., Hennen, J., Cohen, B. M., & Renshaw, P. F. (2003) · Psychiatry Research: Neuroimaging · doi:10.1016/s0925-4927(03)00046-5 · Cited by 140
Brain Bioenergetics and Response to Triiodothyronine Augmentation in Major Depressive Disorder
Iosifescu, D. V., Bolo, N. R., Nierenberg, A. A., Jensen, J. E., Fava, M., & Renshaw, P. F. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.11.020 · Cited by 139
Neurobiological basis of bipolar disorder: Mitochondrial dysfunction hypothesis and beyond
Kato, T. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2016.10.037 · Cited by 126
Lyoo, I. K., Yoon, S., Kim, T.-S., Hwang, J., Kim, J. E., Won, W., Bae, S., & Renshaw, P. F. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12010009 · Cited by 123
Taylor, D. M., Cornelius, V., Smith, L., & Young, A. H. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12343 · Cited by 122
Creatine monohydrate in resistant depression: A preliminary study
Roitman, S., Green, T., Osher, Y., Karni, N., & Levine, J. (2007) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00532.x · Cited by 118
Kato, T., Shioiri, T., Murashita, J., Hamakawa, H., Takahashi, Y., Inubushi, T., & Takahashi, S. (1995) · Psychological Medicine · doi:10.1017/s003329170003347x · Cited by 115
Post, R. M., Altshuler, L. L., Frye, M. A., Suppes, T., Keck, P. E., McElroy, S. L., Leverich, G. S., Luckenbaugh, D. A., Rowe, M., Pizzarello, S., et al. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04811yel · Cited by 113
Multinuclear Magnetic Resonance Spectroscopy Studies of Brain Purines in Major Depression
Renshaw, P. F., Parow, A. M., Hirashima, F., Ke, Y., Moore, C. M., Frederick, B. D., Fava, M., Hennen, J., & Cohen, B. M. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.12.2048 · Cited by 101
Yüksel, Ç., Du, F., Ravichandran, C. T., Goldbach, J. R., Thida, T., Lin, P., Dora, B., Gelda, J., O'Connor, L., Sehovic, S., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.13 · Cited by 95
Studies on the safety of creatine supplementation
Kim, H. J., Kim, C. K., Carpentier, A., & Poortmans, J. R. (2011) · Amino Acids · doi:10.1007/s00726-011-0878-2 · Cited by 94 · cited 1×
“Side-effects reported during this study were rare, mild and transient, similar to previously published trials that have studied creatine monohydrate as a treatment for various medical, neurological and psychiatric conditions or as an ergogenic (Kim et al. 2011).”
ResultKondo, D. G., Sung, Y.-H., Hellem, T. L., Fiedler, K. K., Shi, X., Jeong, E.-K., & Renshaw, P. F. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.07.010 · Cited by 86
Carneiro, A. M., Fernandes, F., & Moreno, R. A. (2015) · Health and Quality of Life Outcomes · doi:10.1186/s12955-015-0235-3 · Cited by 86
Self-citationKondo, D. G., Forrest, L. N., Shi, X., Sung, Y.-H., Hellem, T. L., Huber, R. S., & Renshaw, P. F. (2016) · Amino Acids · doi:10.1007/s00726-016-2194-3 · Cited by 79
Sarris, J., Mischoulon, D., & Schweitzer, I. (2011) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00945.x · Cited by 78
Nierenberg, A. A., Kansky, C., Brennan, B. P., Shelton, R. C., Perlis, R., & Iosifescu, D. V. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412449303 · Cited by 76
Yoon, S., Kim, J. E., Hwang, J., Kim, T.-S., Kang, H. J., Namgung, E., Ban, S., Oh, S., Yang, J., Renshaw, P. F., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.11.027 · Cited by 71 · cited 1×
“A subsample of 34 patients that were enrolled in this trial also participated in multimodal neuroimaging assessments and those who had received creatine supplementation had levels of N-acetyl aspartate (NAA) increased in the prefrontal cortex and rich club connections enriched as evidenced through proton magnetic reso…”
Triacetyluridine (TAU) decreases depressive symptoms and increases brain pH in bipolar patients.
Jensen, J. E., Daniels, M., Haws, C., Bolo, N. R., Lyoo, I. K., Yoon, S. J., Cohen, B. M., Stoll, A. L., Rusche, J. R., & Renshaw, P. F. (2008) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.16.3.199 · Cited by 64
Sonawalla, S. B., Renshaw, P. F., Moore, C. M., Alpert, J. E., Nierenberg, A. A., Rosenbaum, J. F., & Fava, M. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.10.1638 · Cited by 62
Royes, L. F. F., Fighera, M. R., Furian, A. F., Oliveira, M. S., Fiorenza, N. G., Ferreira, J., da Silva, A. C., Priel, M. R., Ueda, E. S., Calixto, J. Β., et al. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2008.04.008 · Cited by 55
Cunha, M. P., Pazini, F. L., Ludka, F. K., Rosa, J. M., Oliveira‐Giacomelli, Á., Budni, J., Ramos-Hryb, A. B., Lieberknecht, V., Bettio, L. E. B., Martin‐de‐Saavedra, M. D., et al. (2015) · Amino Acids · doi:10.1007/s00726-014-1910-0 · Cited by 50
Antidepressant Effects of Open Label Treatment With Coenzyme Q10 in Geriatric Bipolar Depression
Forester, B. P., Harper, D. G., Georgakas, J. E., Ravichandran, C. T., Madurai, N. K., & Cohen, B. M. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000326 · Cited by 47
Tissue-dependent cerebral energy metabolism in adolescents with bipolar disorder
Dudley, J. A., DelBello, M. P., Weber, W. A., Adler, C. M., Strakowski, S. M., & Lee, J. H. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.11.045 · Cited by 46
Dean, O. M., Turner, A., Malhi, G. S., Ng, C., Cotton, S. M., Dodd, S., Sarris, J., Samuni, Y., Tanious, M., Dowling, N., et al. (2014) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2013-1341 · Cited by 43
Relationship between placebo response rate and clinical trial outcome in bipolar depression
Iovieno, N., Nierenberg, A. A., Parkin, S. R., Kim, D. J. H., Walker, R. S. W., Fava, M., & Papakostas, G. I. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.12.016 · Cited by 27
Bartoli, F., Dell’Osso, B. M., Crocamo, C., Fiorillo, A., Ketter, T. A., Suppes, T. M., Clerici, M., & Carrà, G. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.12.021 · Cited by 23
Survey of psychiatrist use of digital technology in clinical practice
Bauer, R., Glenn, T., Monteith, S., Whybrow, P. C., & Bauer, M. (2020) · International Journal of Bipolar Disorders · doi:10.1186/s40345-020-00194-1 · Cited by 20
Common use of dietary supplements for bipolar disorder: a naturalistic, self-reported study
Bauer, M., Glenn, T., Conell, J., Rasgon, N., Marsh, W., Sagduyu, K., MUNOZ, R. A., Lewitzka, U., Bauer, R., Pilhatsch, M., et al. (2015) · International Journal of Bipolar Disorders · doi:10.1186/s40345-015-0029-x · Cited by 15
Implications of a Biosignature Study of the Placebo Response in Major Depressive Disorder
D, M. F. M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.1727 · Cited by 12
Research works printed but not linked: 1
- First MB Spitzer RL Gibbon M Williams Janet BW Structured clinical interview for DSM-IV axis I disorders, clinician version (SCID-CV) 1996 Washington, DC American Psychiatric Press
Cited by
Creatine in health and disease
Kreider, R. B., & Stout, J. R. (2021) · Nutrients · doi:10.3390/nu13020447 · Cited by 227
Effects of creatine supplementation on brain function and health
Forbes, S. C., Cordingley, D. M., Cornish, S. M., Gualano, B., Roschel, H., Ostojic, S. M., Rawson, E. S., Roy, B. D., Prokopidis, K., Giannos, P., et al. (2022) · Nutrients · doi:10.3390/nu14050921 · Cited by 145
Mitochondrial dysfunction as a critical event in the pathophysiology of bipolar disorder
Scaini, G., Andrews, T., Lima, C. N. D. C., Benevenuto, D., STRECK, E. L., & Quevedo, J. (2020) · Mitochondrion · doi:10.1016/j.mito.2020.12.002 · Cited by 94
Balestrino, M., & Adriano, E. (2019) · Medicinal Research Reviews · doi:10.1002/med.21590 · Cited by 90
Creatine for the Treatment of Depression
Kious, B. M., Kondo, D. G., & Renshaw, P. F. (2019) · Biomolecules · doi:10.3390/biom9090406 · Cited by 74
“In a more recent study, Toniolo and colleagues [192] randomized 53 patients with BD type I or II who were currently in a depressive episode to 6g of creatine daily or matched placebo for 6 weeks, as an adjunct to their existing medications.”
Metadata
- Authors
- Toniolo, R. A., Silva, M., Fernandes, F. D. B. F., Amaral, J. A. D. M. S., Dias, R. D. S., & Lafer, B.
- Affiliations
- Universidade de São Paulo (BR)
- Corresponding author
- Toniolo, Ricardo Alexandre
- Venue
- Journal of Neural Transmission
- Published
- 2017-11-24
- Volume
- 125
- Issue
- 2
- Pages
- 247-257
- ISSN
- 0300-9564 (ISSN-L)
- 1435-1463
- PMC
- PMC5775367
- OpenAlex
- W2770274569
- Cited by
- 50
- References
- 55
- Citations by year
- 2026: 10 · 2025: 9 · 2024: 5 · 2023: 4 · 2022: 6 · 2021: 5 · 2020: 7 · 2019: 4
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of Neural Transmission (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Brain and Behavior Research Foundation (20202)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- creatine monohydrate, bipolar depression, bipolar disorder, adjunctive therapy, mitochondrial dysfunction, brain bioenergetics, nutraceuticals, depression remission, Montgomery-Asberg Depression Rating Scale, subsyndromal depressive symptoms, placebo comparison, mood stabilizers
- MeSH terms
- Proof of Concept Study, Adult, Antidepressive Agents, Antioxidants, Bipolar Disorder, Creatine, Double-Blind Method, Humans, Middle Aged, Dietary Supplements
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.